Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 3Vipivotide literatureNatureTop journal2022

Hundreds of COVID trials could provide a deluge of new drugs.

Not reported in abstract.

Read at NatureAdd to compare

Where it sits

this study against the rest of the vipivotide corpus
3
Preclinical · this one
0
Observational
0
Open-label
0
Randomised
0
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2022

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Vipivotide corpus

DPlitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.Science (New York, N.Y.) · 2021DSARS-CoV-2 dependence on host pathways.Science (New York, N.Y.) · 2021